PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 128 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $174,573 | -43.2% | 10,466 | -5.9% | 0.00% | -100.0% |
| Q2 2023 | $307,107 | -31.3% | 11,119 | -72.9% | 0.00% | 0.0% |
| Q4 2022 | $446,983 | -53.8% | 40,970 | -64.3% | 0.00% | -50.0% |
| Q3 2022 | $967,000 | +86.3% | 114,688 | +655.7% | 0.00% | +100.0% |
| Q4 2021 | $519,000 | -29.8% | 15,177 | -63.6% | 0.00% | 0.0% |
| Q3 2021 | $739,000 | -38.1% | 41,677 | +56.6% | 0.00% | -50.0% |
| Q2 2021 | $1,194,000 | +51.7% | 26,608 | -12.4% | 0.00% | +100.0% |
| Q1 2021 | $787,000 | +66.7% | 30,387 | +29.7% | 0.00% | 0.0% |
| Q4 2020 | $472,000 | +5.8% | 23,423 | +2.7% | 0.00% | 0.0% |
| Q3 2020 | $446,000 | +457.5% | 22,800 | +100.9% | 0.00% | – |
| Q1 2020 | $80,000 | -50.0% | 11,347 | -50.0% | 0.00% | – |
| Q4 2019 | $160,000 | -41.2% | 22,687 | 0.0% | 0.00% | – |
| Q3 2019 | $272,000 | – | 22,687 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |